Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | SELE | P16581 | 1/20 | 0.31 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22509663 | 0.78 | SELE (0.34) | SLC22A12PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL17148436 | 0.78 | SELE (0.34) | SLC22A12CHEK1PDE4APDE4BPDE4C | |
| SCHEMBL20646662 | 0.78 | SLC22A12 (0.33) | SLC22A12CHEK1PDE4APDE4BPDE4C | |
| SCHEMBL17154070 | 0.71 | MAPT (0.48) | PDE4APDE4BPDE4CPDE4DHTT | |
| SCHEMBL22857603 | 0.69 | LIMK1 (0.37) | SLC22A12 | |
| SCHEMBL17365918 | 0.68 | ADORA2A (0.40) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL15586636 | 0.68 | PDE4A (0.37) | SLC22A12PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL18380981 | 0.66 | PDE4A (0.35) | PDE4APDE4BPDE4CPDE4DHTT | |
| SCHEMBL5004901 | 0.66 | SRC (0.41) | PDE4APDE4BPDE4CPDE4DHTT | |
| SCHEMBL22857600 | 0.66 | HSD17B10 (0.33) | SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398117-A1 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| US-11541056-B2 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide derivatives | NOVARTIS AG (CH) | 2023-01-03 | — | — | US | disclosed |
| US-20210251996-A1 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | NOVARTIS AG (CH) | 2021-08-19 | — | — | US | disclosed |
| US-20210002285-A1 | N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide Derivatives | NOVARTIS PHARMA AG (CH) | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541056-B2 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide derivatives | PAH, PKD1, REN | SLC22A12 1691/4885CHEK1 4577/4885PDE4A 780/4885 |
| US-20230398117-A1 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | PAH, PKD1, REN | SLC22A12 1691/4885CHEK1 4577/4885PDE4A 780/4885 |
| US-20210251996-A1 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | PAH, PKD1, REN | SLC22A12 1691/4885CHEK1 4577/4885PDE4A 780/4885 |
| US-20210002285-A1 | N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide Derivatives | PAH, PARK7, PKD1 | SLC22A12 1328/4885CHEK1 4369/4885PDE4A 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.